PolyPid (PYPD)
(Delayed Data from NSDQ)
$3.46 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:29 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PYPD 3.46 0.00(0.00%)
Will PYPD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PYPD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PYPD
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think PolyPid Ltd. (PYPD) Could Surge 206%: Read This Before Placing a Bet
PYPD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
All You Need to Know About PolyPid Ltd. (PYPD) Rating Upgrade to Buy
Wall Street Analysts Believe PolyPid Ltd. (PYPD) Could Rally 223%: Here's is How to Trade
Other News for PYPD
PolyPid files to sell 3.91M ordinary shares for holders
PolyPid files to sell 3.91M ordinary shares for holders
PolyPid (PYPD) Receives a Hold from Barclays
Buy Rating Affirmed for PolyPid on D-PLEX Clinical Progress and Potential Early Approval
PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript Highlights: Financial Updates and Clinical ...